These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 25888551)

  • 1. Parkinson's disease dementia: a neural networks perspective.
    Gratwicke J; Jahanshahi M; Foltynie T
    Brain; 2015 Jun; 138(Pt 6):1454-76. PubMed ID: 25888551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can neuroimaging predict dementia in Parkinson's disease?
    Lanskey JH; McColgan P; Schrag AE; Acosta-Cabronero J; Rees G; Morris HR; Weil RS
    Brain; 2018 Sep; 141(9):2545-2560. PubMed ID: 30137209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dynamic computational model of the parallel circuit on the basal ganglia-cortex associated with Parkinson's disease dementia.
    Yang H; Yang X; Yan S
    Biol Cybern; 2024 Apr; 118(1-2):127-143. PubMed ID: 38644417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence of clinical and neurodegeneration events in Parkinson's disease progression.
    Oxtoby NP; Leyland LA; Aksman LM; Thomas GEC; Bunting EL; Wijeratne PA; Young AL; Zarkali A; Tan MMX; Bremner FD; Keane PA; Morris HR; Schrag AE; Alexander DC; Weil RS
    Brain; 2021 Apr; 144(3):975-988. PubMed ID: 33543247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.
    Hall H; Reyes S; Landeck N; Bye C; Leanza G; Double K; Thompson L; Halliday G; Kirik D
    Brain; 2014 Sep; 137(Pt 9):2493-508. PubMed ID: 25062696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interplay of cholinergic function, attention, and falls in Parkinson's disease.
    Yarnall A; Rochester L; Burn DJ
    Mov Disord; 2011 Dec; 26(14):2496-503. PubMed ID: 21898597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resting-state fMRI in Parkinson's disease patients with cognitive impairment: A meta-analysis.
    Wolters AF; van de Weijer SCF; Leentjens AFG; Duits AA; Jacobs HIL; Kuijf ML
    Parkinsonism Relat Disord; 2019 May; 62():16-27. PubMed ID: 30580907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The morphological basis of dementia in Parkinson's disease.
    Ball MJ
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):180-4. PubMed ID: 6713315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognition in Parkinson's Disease.
    O'Callaghan C; Lewis SJG
    Int Rev Neurobiol; 2017; 133():557-583. PubMed ID: 28802933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ophthalmic disorders as a manifestation of Parkinson's disease].
    Chesnokova NB; Pavlenko TA; Ugrumov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):124-131. PubMed ID: 29053133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The functional anatomy of noradrenergic neurons in Parkinson's disease.
    Soldani P; Fornai F
    Funct Neurol; 1999; 14(2):97-109. PubMed ID: 10399622
    [No Abstract]   [Full Text] [Related]  

  • 12. Morphological substrates of dementia in parkinsonism. A critical update.
    Jellinger KA
    J Neural Transm Suppl; 1997; 51():57-82. PubMed ID: 9470129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
    Ztaou S; Maurice N; Camon J; Guiraudie-Capraz G; Kerkerian-Le Goff L; Beurrier C; Liberge M; Amalric M
    J Neurosci; 2016 Aug; 36(35):9161-72. PubMed ID: 27581457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease.
    O'Keeffe GW; Sullivan AM
    Parkinsonism Relat Disord; 2018 Nov; 56():9-15. PubMed ID: 29934196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disturbances in higher function in Parkinson's disease.
    Tamaru F
    Eur Neurol; 1997; 38 Suppl 2():33-6. PubMed ID: 9387801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the extranigral aspects of Parkinson disease.
    Lim SY; Fox SH; Lang AE
    Arch Neurol; 2009 Feb; 66(2):167-72. PubMed ID: 19204152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal communication breakdown in neurotransmitter systems in Alzheimer's and Parkinson's dementias.
    Chan-Palay V
    J Neurocytol; 1990 Oct; 19(5):802-6. PubMed ID: 1706418
    [No Abstract]   [Full Text] [Related]  

  • 18. Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease.
    Silva MF; Faria P; Regateiro FS; Forjaz V; Januário C; Freire A; Castelo-Branco M
    Brain; 2005 Oct; 128(Pt 10):2260-71. PubMed ID: 16000338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cognitive impairment in Parkinson's disease].
    Tachibana H
    Seishin Shinkeigaku Zasshi; 2013; 115(11):1142-9. PubMed ID: 24450147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.